Enrique Velasquez, MD
Cardiovascular Disease · Huntsville, ALNPI 1972574051
Payments from drug & device makers
Across 737 payments — averaging $168.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$41K
- Boehringer Ingelheim International GmbH$39K
- Boehringer Ingelheim Pharma GmbH & Co.kg$30K
- AstraZeneca$4K
- Novartis$2K
- Boston Scientific$1K
- plus $7K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 20 | $40,868 |
| Boehringer Ingelheim International GmbH | 136 | $39,216 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 11 | $29,989 |
| AstraZeneca | 38 | $3,900 |
| Novartis | 113 | $2,062 |
| Boston Scientific | 66 | $1,424 |
| Johnson & Johnson | 72 | $1,054 |
| Amgen | 49 | $1,021 |
| Pfizer | 47 | $920 |
| Boehringer Ingelheim | 31 | $695 |
| E.r. Squibb & Sons, L.L.C. | 25 | $611 |
| Regeneron Healthcare Solutions, Inc. | 21 | $462 |
| Novo Nordisk | 16 | $276 |
| Bayer | 13 | $262 |
| Sanofi-aventis U.S. LLC | 14 | $244 |
| Abbott | 5 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $189 |
| Gilead | 16 | $181 |
| Esperion Therapeutics, Inc. | 9 | $164 |
| Actelion Pharmaceuticals US, Inc. | 7 | $138 |
| United Therapeutics Corporation | 3 | $99 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Heartflow, Inc. | 1 | $47 |
| Siemens Medical Solutions USA, Inc. | 2 | $37 |
| Chiesi USA, Inc. | 3 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Endotronix, Inc. | 1 | $17 |
How this compares
$124,292 in reported general payments places this provider in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Huntsville
- Walter HaughtHuntsville$1.6M
- Shi-Chi ChengHuntsville$1.2M
- Vernon HunterHuntsville$778K
- Phillip LaneyHuntsville$283K
- Michael RidnerHuntsville$216K
- James MurphyHuntsville$115K
- Rashida AbbasHuntsville$45K
- Warren StricklandHuntsville$14K
- Mustafa AhmedBirmingham$2.5M
- Brian FoleyAlexander City$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.